Designing Antibiotics with Inherent Efflux Resistance: In Vitro and In Vivo Results

A novel Efflux Resistance Breaker strategy for designing antibiotics intrinsically resistant to efflux, using fluoroquinolones as a model class. The dataset likely contains results from in vitro assays and in vivo mouse models, including MIC values, IC50 data, and PK/PD profiles. It was authored by Mark Laws and last updated on 2026-05-29.

Use Cases

• Training predictive models for antibiotic activity based on MIC reduction data mentioned in the description.
• Analyzing structure-activity relationships for fluoroquinolone derivatives designed to evade efflux pumps.
• Evaluating pharmacokinetic and pharmacodynamic profiles for lead compounds like KSN-L22 and BL-7.
• Benchmarking in vivo efficacy using bacterial load reduction data from a murine thigh infection model.

Strengths

• Includes specific quantitative results, such as a 512-fold reduction in MIC and IC50 values of ~3.8 μg/mL.
• Reports activity against a range of clinically relevant pathogens, including MRSA, VRE, and A. baumannii.
• Contains in vivo efficacy data showing a >4-log bacterial load reduction in a mouse model.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 2.9 KB, indicating a limited scope of data.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from the described research study.

Freshness

Last updated 2026-05-29 04:48:44; freshness should be verified.